BRD4 is implicated in the pathogenesis of a number of different cancers. It is also the target of translocation t(15;19) that accounts for the highly aggressive NUT midline carcinoma (NMC). We discovered that t(15;19) NMC cells display the ability to grow into stem cell-like spheres and express an exceptionally high level of the stem cell marker, SOX2. The BRD4-NUT fusion oncogene resulting from t(15;19) translocation is required for the abnormal activation of SOX2, which drives the stem cell-like proliferation and cellular transformation in NMC cells. SOX2 knockdown phenocopies the effects of BRD4-NUT inhibition, whereas ectopic SOX2 expression rescues the phenotype. The BRD4-NUT-induced abnormal SOX2 activation was observed in multiple NMC cell lines as well as in NMC primary tumors. We further demonstrate that BRD4-NUT oncoprotein recruits p300 to stimulate transcription activation and that inhibition of p300 represses SOX2 transcription in NMC cells. These studies identify this stem cell marker as a novel BRD4-NUT target that supports the highly aggressive transforming activity of t(15;19) carcinomas. Our study provides new mechanistic insights for understanding how alteration of BRD4 function by BRD4-NUT oncogene leads to the highly malignant NMC carcinoma. Because abnormal stem cell self-renewal is frequently observed during tumor formation and metastasis, the aberrant stem cell-like proliferation associated with BRD4 dysregulation observed in NMC carcinoma may have implications for studying the oncogenic mechanism of other BRD4-associated tumors. Cancer Res; 74(12); 1-12. Ó2014 AACR.
Introduction
The t (15;19) translocation is one of the first few somatically acquired recurrent chromosome translocations identified in squamous cell carcinomas (1) . These translocation-induced tumors, termed NUT midline carcinoma (NMC), represent the most lethal subset of squamous cell carcinomas (2) . All of the known t(15;19)-positive carcinomas metastasize rapidly and are extremely aggressive with a median survival of <7 months (2) . NMC tumors typically display remarkably simple karyotypes, suggesting that this translocation may represent a shortcut to bypass the complex process of accumulating genetic mutations that are typically required for developing invasive squamous cell carcinomas (2) . The simple genetic alteration in NMCs also suggests that this translocation may induce a potent transforming activity in the affected chromosome regions (2, 3) . These carcinomas respond poorly to standard chemotherapeutic strategies (2) . Therefore, it is important to determine the oncogenic mechanisms of these carcinomas for developing novel therapeutic approaches.
The BRD4 gene on chromosome 19 and NUT gene (Nuclear protein in testis, aka NUTM1) on chromosome 15 are targets of translocation t (15;19) (1) . BRD4 belongs to the bromodomain and extraterminal (BET) protein family. It is normally expressed as naturally occurring long and short isoforms. The t(15;19) translocation breakpoint splits the coding sequence of the long BRD4 transcript approximately in half, resulting in the in-frame fusion of the BRD4 N-terminal double bromodomains and extraterminal domain with nearly the entire sequence of NUT (1) . Interestingly, some chromosomal translocations also lead to the fusion of NUT to BRD3 encoding another BET protein (4) . These observations suggest that fusion of NUT with a BET protein may drive the oncogenic activity of these highly aggressive NMCs.
BRD4 binds to acetylated chromatin through its double bromodomains. It facilitates transcriptional regulation by recruiting P-TEFb, mediators, and other transcriptional activators (5) (6) (7) . BRD4 has been identified as a critical therapeutic target in a number of different cancers (8) (9) (10) (11) , in which BRD4 has been shown to regulate c-MYC (7, 8, 10, 11) . Dissociation of BRD4 from chromatin also leads to selective inhibition of other key oncogenes in tumor cells (7) .
Given the established connection of BRD4 to cancer development, the simple BRD4-NUT genetic alteration in t (15;19) carcinomas provides an important tool to determine how dysregulation of this gene leads to cancer. The dual bromodomains tether the BRD4-NUT fusion oncoprotein to chromatin (4, 12, 13) . BRD4-NUT causes malignancy by blocking NMC differentiation and driving tumor growth (2, 4, 14) . The NUT moiety of the fusion protein also sequesters histone acetyl-transferases to regional chromatin, leading to global transcriptional repression and inhibition of cellular differentiation (12, 13) . c-MYC has been shown to be a downstream target of BRD4-NUT that blocks NMC cellular differentiation (15) .
Despite these current developments, it is still unclear how the BRD4-NUT oncogene drives such highly aggressive carcinomas and why these tumors are unequivocally resistant to conventional chemotherapy. In this study, we discover that NMC cells have the potential to grow into stem cell-like spheres. This stem cell-like feature was attributed to an exceptionally high-level expression of sex-determining region Y-box protein 2 (SOX2). SOX2 is a transcription factor essential for stem cell self-renewal and pluripotency (16) . Although SOX2 expression is normally restricted to stem cells, aberrant overexpression and amplification of SOX2 has been reported in many different types of solid tumors (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . SOX2-induced aberrant stem cell self-renewal has been linked to its ability to promote tumorigenicity and poorly differentiated morphology (17, 25, 32, 33) . However, the mechanism that regulates SOX2 expression in these cancers is not clearly understood. We demonstrate that BRD4-NUT drives the abnormally high SOX2 expression in NMCs to promote the aberrant stem cell-like growth feature, which underlies the highly aggressive transforming activity of the t(15;19) translocation. Our study identifies SOX2 as a novel target for BRD4-NUT as well as a key oncogenic driver of NMC tumor growth.
Materials and Methods
Cell culture, gene knockdown, and stable cells HCC2429 (Dr. T.P. Dang, University of Virginia, Charlottesville, VA), Ty-82 (JCRB Cell Bank), 10-15 (15) , and 14169 cells were maintained in RPMI 1640 (Invitrogen) with 10% fetal bovine serum (Hyclone) and 1% penicillin/streptomycin (Invitrogen). The 10-15 and 14169 cells were provided by Christopher French, Harvard Medical School, Boston, MA. All four cell lines have been authenticated using BRD4-NUT Western blotting, Immunofluorescent staining, and DNA sequencing as described in the manuscript.
The nontarget control, BRD4, NUT, and SOX2 siRNAs were purchased from Dharmacon. For siRNA knockdown, cells were transfected using DharmaFECT reagents (Thermo Scientific). For SOX2 double knockdown, cells were reseeded at 24 hours after the first siRNA transfection and retransfected with the same siRNA 12 hours later. HCC2429 SOX2 stable cells were generated as described in the Supplementary Methods.
Western blot analysis
These analyses were performed using standard protocols. Additional experimental details are provided in the Supplementary Methods.
Immunofluorescent staining
Immunofluorescent staining was performed as previously described (13) . Specific antibodies and imaging methods are described in the Supplementary Methods.
Sphere formation assay
Basic embryonic stem cells (ESC) medium was prepared by supplementing knockout DMEM/F12 (Invitrogen) with 0.5% N-2 (Invitrogen), 1% B27 (Invitrogen), 0.05% BSA (Invitrogen), 1% GlutaMAX (Invitrogen), and 1% Pen-strep. To prepare full ESC medium, basic embryonic stem medium was supplemented with 10 ng/mL human BMP-4 (R&D), 1,000 U/mL LIF (Millipore), and 1. 
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using a published method (34) with some modifications. Formaldehyde was added directly to cell culture media at a final concentration of 1%. After incubation for 10 minutes at room temperature, fixation was stopped by adding glycine to a final concentration of 0.125 mol/L. Cells were scraped, collected, centrifuged, and swelled in cell lysis buffer (5 mmol/L PIPES, pH 8.0, 85 mmol/L KCl, 1% NP-40, 0.1 mmol/L PMSF, and 1 mg/mL leupeptin, aprotinin, and pepstatin A). After 1-hour incubation on ice, nuclei were collected by centrifugation at 4,000 rpm for 10 minutes at 4 C, resuspended in nuclei lysis buffer (50 mmol/L Tris-HCl, pH 8.0, 1% SDS, 10 mmol/L EDTA, 0.1 mmol/L PMSF, and 1 mg/mL leupeptin, aprotinin, and pepstatin A) and incubated on ice for 10 minutes. Samples were sonicated on ice to an average of 500 bp DNA length and centrifuged at 14,000 rpm. The chromatin solution was precleared with Staph A cells (preblocked with 1 mg/mL sheared herring sperm DNA and 1 mg/mL BSA for at least 4 hours at 4 C) for 15 minutes at 4 C. Chromatin from about 10 7 cells was incubated with 3 mg of normal rabbit IgG (NR, Upstate), or affinity-purified rabbit polyclonal antibodies generated in our lab for BRD4 C (recognizes BRD4 aa 1313-1362) or NUT. After rotating at 4 C overnight, chromatin and antibody complexes were immunoprecipitated by mixing with preblocked Staph A cells at room temperature for 15 minutes. Immunoprecipitates were centrifuged at 14,000 rpm for 3 minutes. The supernatant from the NR antibody sample was saved as total chromatin input. Staph A immuno-complexes were washed twice with dialysis buffer (50 mmol/L Tris-HCl, pH 8.0, 2 mmol/L EDTA, 0.2% Sarkosyl, 0.1 mmol/L PMSF) and 4 times with ChIP wash buffer (100 mmol/L Tris, pH 9.0, 500 mmol/L LiCl, 1% NP-40, 1% deoxycholic acid, 0.1 mmol/L PMSF). Immuno-complexes were eluted from the Staph A cells using elution buffer (50 mmol/L NaHCO 3 , 1% SDS). Crosslinks were reversed by adding NaCl to a final concentration of 300 mmol/L and incubating at 67 C overnight. RNA was removed by incubation with RNase A at 37 C for 30 to 60 minutes. DNA samples were purified using PCR Purification Kit (Qiagen) and eluted in 80 mL EB buffer. Five microliters immunoprecipitated DNA or 1/50 of total input chromatin was used in real-time PCR reaction with primers listed in Supplementary Table S1 .
Statistical analyses
Statistical analysis was performed using unpaired t test of GraphPad Prism software (Version 5.0) to compare the data from the control and experimental groups. A 2-tailed P value of <0.05 was considered statistically significant.
Visualization of in situ activation of the LacO transgene array
The LacI-CHERRY constructs were generated as described in Supplementary Methods. U2OS 2-6-3 YFP-MS2 stable cell line was from Dr. S.M. Janicki (35) and has been tested in the in situ transcription assay as described in the Results. The cells were transfected using Fugene HD reagent (Roche) and fixed at 24-hour posttransfection. Immunofluorescent staining, imaging, quantitative single-cell image analysis were performed as described in the Supplementary Methods.
Immunohistochemistry
Immunohistochemistry on formalin-fixed, paraffin-embedded archival sections of primary human NMC was performed using a rabbit anti-SOX2 monoclonal antibody (1:100 dilution, clone D6D9; Cell Signaling) following pressure cooker antigen retrieval (citrate buffer; pH 6). Photographs were taken under Â400 magnification.
Soft agar assay
The soft agar assay was performed as described previously (36) . Additional agar preparation and experimental details are provided in the Supplementary Methods.
Reverse transcription-qPCR
Total RNA was isolated using NucleoSpin RNA II Kit (Macherey-Nagel). Reverse transcription (RT) was performed using M-MLV reverse transcriptase (Invitrogen). Quantitative real-time PCR was performed using a CFX96 Real-Time PCR Detection System (Bio-Rad) with IQ SYBR Green Supermix (Bio-Rad). Primer sequences are shown in Supplementary  Table S1 . Additional experimental details are fully described in the Supplementary Methods.
Results

SOX2 gene is expressed at an exceptionally high level in NMC cells
HCC2429 is a rapidly growing cell line established from a t(15;19) translocation NMC (3). It carries 1 intact BRD4 locus and expresses normal BRD4 as well as BRD4-NUT (13) . In normal medium, most HCC2429 cells grow in a monolayer and display an epithelial morphology ( Supplementary Fig. S1A ). However, a small population of the cells appeared round and refractile, displaying some morphologic features of ESC. We therefore tested HCC2429 in ESC medium. Interestingly, when the cells attached to the plates were switched to ESC medium, they gradually became nonadherent and grew into stem cell sphere-like, refractile colonies (Supplementary Fig. S1B and S1C). After seeding HCC2429 directly in basic ESC medium for 5 days, single cells could grow into condensed stem cell-like spheres with a translucent, light-refractive appearance (Supplementary Fig. S1D-S1F ). In addition, the sphere-forming ability was maintained in these cells after continued passages.
Because this anchorage-independent growth represents one of the important characteristics of cancer stem cells and the sphere-forming ability was used to measure self-renewal potential for these cells (37) (38) (39) (40) , we further examined other stem cell features in HCC2429. Patches of HCC2429 cells were found to express alkaline phosphatase, a stem cell membrane marker ( Supplementary Fig. S2 ), suggesting that HCC2429 has gained some stem cell-like growth properties.
To understand the stem cell-like feature of HCC2429, we examined the major stem cell pluripotency markers in these cells (Fig. 1A) . A markedly higher level of SOX2 protein was observed in HCC2429 compared with mouse embryonic stem (mES) cells (Fig. 1A) . However, OCT4 or NANOG was not detected (Fig. 1A) . High level of SOX2 was also detected in C33A but was absent in all other cancer cell lines tested (Fig.  1A ). In contrast, low level of c-MYC, an established target of BRD4-NUT (15), was detected in HCC2429 and nearly all of the other non-NMC cancer cell lines tested (Fig. 1A) . We therefore focused on the novel and unique induction of SOX2 in HCC2429.
Abundant SOX2 transcripts were detected in HCC2429 (Fig.  1B) . SOX2 protein was also clearly detected in HCC2429, in which BRD4-NUT characteristically displayed punctate nuclear dots ( Fig. 1C and ref. 13 ).
To ensure that SOX2 overstimulation is not an NMC cell culture phenomenon, we also performed SOX2 immunohistochemical staining on five different cases of primary NMC tumors. Four of these NMCs are BRD4-NUT positive and one is BRD3-NUT positive. Interestingly, SOX2 was highly expressed in four of the five primary tumors ( Fig. 2A-D) , including the BRD3-NUT-positive case (Fig. 2D ). This study provided in vivo evidence for the SOX2 overstimulation in NMC tumors.
Preferential SOX2 overexpression has been tied to stem celllike phenotypes displayed by high-grade tumors (41) . Our results therefore led us to hypothesize that highly expressed SOX2 may contribute to the stem cell-like growth features and the highly aggressive oncogenic potential of HCC2429.
JQ1
þ suppresses SOX2 expression, induces differentiation, and abrogates sphere formation The bromodomain inhibitor, JQ1 þ , dissociates BRD4 and BRD4-NUT from acetylated chromatin (14) , and represses their downstream target genes (8, 10, 11) . We therefore tested the JQ1 þ effect on SOX2 expression (Fig. 3 ). HCC2429 treated with 100 nmol/L JQ1 þ showed significantly diminished SOX2 protein compared with the cells treated with the inactive stereoisomer JQ1 À (Fig. 3A) . JQ1 þ also displayed a dose-dependent inhibition on SOX2 expression ( Supplementary Fig. S3 ). In addition, JQ1
þ -treated cells showed a decreased SOX2 mRNA level compared with JQ1
À -treated cells (Fig. 3B ). This inhibition was observed in HCC2429 treated with 500 nmol/L of JQ1 þ for 6 hours to avoid indirect effect on cell proliferation and other gene expression, demonstrating a direct inhibition of SOX2 expression by JQ1 þ .
HCC2429 shows poorly differentiated cellular features (13) . Interestingly, as SOX2 was reduced in JQ1 þ cells, there was an increase in cellular differentiation, as indicated by the induction of the terminal squamous differentiation marker, involucrin (Fig. 3A) . Involucrin gradually appeared after day 3 in JQ1 þ , and reached a much higher level on day 5, whereas no involucrin was detected in JQ1 À cells (Fig. 3A) .
These results demonstrated an inverse correlation between the SOX2 level and cellular differentiation. Moreover, JQ1 þ treatment dramatically inhibited sphere formation (Fig. 3C ).
These data suggest that the acetyl-histone binding ability of BRD4, BRD4-NUT, or both is required to support SOX2 upregulation and the undifferentiated stem cell-like growth of HCC2429.
þ dissociates BRD4 and BRD4-NUT from the SOX2
regulatory regions
We tested how JQ1 þ affects the occupancy of BRD4 and BRD4-NUT at the SOX2 gene. BRD4 ChIP was performed using an antibody that specifically recognizes the C-terminus of native BRD4, but not BRD4-NUT, whereas BRD4-NUT ChIP used a NUT-specific antibody. Primers spanning the SOX2 gene Enhancer I (SRRI), promoter, and Enhancer II (SRRII) were used in ChIP q-PCR to detect the binding of BRD4 and BRD4-NUT to these regions (Fig. 3D ). In addition, primers targeting two nonspecific control regions (NC1 and NC2) outside of the SOX2 gene were used as negative controls ( Fig. 3E and F ). BRD4 and BRD4-NUT ChIPs were performed using HCC2429 treated with 500 nmol/L of either JQ1 þ or JQ1 À for 6 hours, as in the RTqPCR analysis ( were found to be specifically recruited to the SOX2 gene compared with the negative control regions ( Fig. 3E and F ). BRD4 and BRD4-NUT occupy the SOX2 core proximal promoter, enhancers, and super-enhancer regions (17, (42) (43) (44) , with the binding peaks at the À1.5k and À900 regions surrounding the SOX2 core promoter (44) . JQ1 þ significantly inhibited the binding of both BRD4 and BRD4-NUT to the SOX2 core promoter and enhancers ( Fig. 3E and F ).
BRD4-NUT knockdown inhibits SOX2 expression and sphere formation while inducing differentiation To specifically determine the role of BRD4 or BRD4-NUT on SOX2 gene regulation, we tested how knockdown of BRD4 or BRD4-NUT affects SOX2 expression (Fig. 4 and Supplementary Fig. S4 ). As shown in Fig. 4A and Supplementary S4A, SOX2 protein was specifically reduced in BRD4-NUT knockdown cells. Compared with control siRNA treatment, BRD4-NUT knockdown also reduced the SOX2 mRNA levels ( Fig. 4B and Supplementary Fig. S4B) . Surprisingly, the SOX2 mRNA level was not affected by knockdown of the long isoform of BRD4 (Fig. 4C) . These results suggest that BRD4-NUT plays a more important role than BRD4 in driving SOX2 upregulation.
Similar to JQ1 þ treatment, involucrin was also significantly induced in NUT siRNA-treated cells at 48 hours posttransfection ( Fig. 4A and Supplementary Fig. S4A ). Cells treated with NUT siRNA also showed markedly impaired sphere formation (Fig. 4D) . Because BRD4-NUT knockdown downregulates SOX2 expression and inhibits stem cell-like sphere formation, BRD4-NUT is likely playing an important role in supporting SOX2 expression and the stem cell-like proliferation in HCC2429.
SOX2 knockdown induces differentiation while inhibiting sphere formation and transformation SOX2 enforces self-renewal in ESCs by promoting pluripotency-related genes and suppressing differentiation-related genes (16) . SOX2 overexpression correlates with advanced malignancy grade and poor prognosis in a number of solid tumors (18, 19, 21) . Both JQ1 þ and NUT siRNA-induced inhibition of SOX2 expression correlates with a decrease in sphere formation and an increase in differentiation (Figs. 3, 4 , and Supplementary Fig. S4 ), raising the possibility that high SOX2 expression in HCC2429 may support proliferation in the stem cell-like manner while inhibiting differentiation. To directly test this, we performed siRNA-mediated SOX2 knockdown in HCC2429. Single transfection of SOX2 siRNA resulted in moderate SOX2 knockdown, likely because SOX2 is robustly expressed in HCC2429 (Fig. 1) . SOX2 siRNAs were therefore transfected twice sequentially into the cells to achieve a more efficient knockdown (Fig. 5A ). Similar to JQ1 þ and NUT siRNA treatments (Figs. 3, 4 and Supplementary Fig. S4 ), an induction of involucrin was observed specifically in SOX2 knockdown cells (Fig. 5A) , providing direct evidence that SOX2 functions as a key BRD4-NUT downstream target to block cellular differentiation. Because SOX2 is essential for stem cell self-renewal, we speculated that SOX2 expressed in HCC2429 might be the major driving force for the cells to grow into stem cell-like spheres. Indeed, the percentage of cells forming spheres was significantly reduced in cells treated with SOX2 siRNA (Fig. 5B) , confirming that high level of SOX2 is needed to support sphere growth. SOX2 knockdown also moderately inhibited HCC2429 proliferation under normal culture conditions ( Supplementary  Fig. S5) . Because SOX2 expression enhances colony formation in soft agar (28), we tested how SOX2 knockdown affects the growth of HCC2429 in a soft agar assay. Compared with control cells, SOX2 knockdown caused a nearly 50% reduction in the number of colonies grown in soft agar (Fig. 5C  and D) , indicating a reduced transformation potential in SOX2 knockdown cells. These results suggest that SOX2 functions as one of the target genes regulated by BRD4-NUT to drive the aberrant stem cell-like property and cellular transformation in HCC2429.
Ectopically expressed SOX2 rescues the cellular differentiation induced by JQ1
þ and NUT siRNA
The data so far suggest that BRD4-NUT drives SOX2 overexpression to support the highly transformed and poorly differentiated phenotype of HCC2429. To directly test the functional link between BRD4-NUT and SOX2, we generated an HCC2429 cell line stably expressing an Xpress-tagged SOX2 from an inducible promoter. Robust Xpress-SOX2 expression could be detected when the cells were treated with 0.1 mg/mL doxycycline (Dox; Fig. 5E and Supplementary Fig. S6A ). JQ1 Fig. S6B ). Interestingly, SOX2 stable cells treated with both JQ1 þ and Dox maintained an undifferentiated morphology ( Supplementary Fig. S6B ). In contrast, in the vector control stable cells, the JQ1 þ -induced differentiation was not attenuated by Dox treatment (Supplementary Fig. S6B ). In the absence of Dox, SOX2 stable cells treated with JQ1 þ showed robustly increased involucrin compared with JQ1 À cells (Supplementary Fig. S6A ). This JQ1 þ -stimulated involucrin expression was prevented in cells induced to express SOX2 ( Supplementary Fig. S6A ).
We also tested if Dox-induced SOX2 expression can rescue the differentiation caused by BRD4-NUT knockdown. NUT siRNA also specifically reduced the endogenous SOX2 expression without affecting the ectopically expressed SOX2 (Fig. 5E ). More importantly, the BRD4-NUT knockdown-induced involucrin expression was markedly inhibited in cells induced to express SOX2 (Fig. 5E ). Because exogenous SOX2 was able to suppress differentiation induced by JQ1 þ and BRD4-NUT knockdown, these results rule out off-target effects and support that SOX2 is an important target gene of BRD4-NUT that blocks cellular differentiation.
Ectopic SOX2 expression rescues the growth inhibition caused by JQ1 þ and NUT siRNA
We next tested whether exogenous SOX2 could rescue the growth inhibition caused by JQ1 þ and NUT siRNA. In the absence of Dox, JQ1 þ leads to inhibition of cellular proliferation as indicated by the reduction of cells expressing the proliferation marker, Ki67 (Supplementary Fig. S6C and  S6D ). In cells treated with both JQ1 þ and Dox, proliferation was partially rescued (Supplementary Fig. S6C and S6D ). BRD4-NUT knockdown also inhibited cellular proliferation, reducing the Ki67 staining in SOX2 stable cells without Dox induction ( Fig. 5F and G) . This inhibition was also rescued by Doxinduced SOX2 expression ( Fig. 5F and G) . Together, these results suggest that SOX2 plays an important role not only in the BRD4-NUT-mediated blockade of differentiation but also in the maintenance of NMC proliferation.
BRD4-NUT stimulated SOX2 overexpression also inhibits differentiation and drives sphere formation in other NMCs
This study established that BRD4-NUT stimulates SOX2 expression to support proliferation and to inhibit differentiation. To ensure that this is not an isolated phenomenon restricted to HCC2429, we examined other NMC cell lines, including 10-15 (15), 14169 (unpublished), and Ty-82 (45). BRD4 was detected in these NMCs, confirming the presence of a wild-type BRD4 locus (Fig. 6A) . Western blots also detected BRD4-NUT in 10-15, 14169, and Ty-82 (Fig. 6A) . Sequencing analysis showed that t(15:19) translocation breaks BRD4 gene at different sites in these tumors (Supplementary Fig. S7 ; ref. 46) , resulting in the fusion oncogene isoforms that encode BRD4-NUT proteins with different sizes (Fig. 6A) . Furthermore, immunofluorescent staining detected the characteristic punctate nuclear pattern of BRD4-NUT in all 3 cell lines (Fig. 6B) . Abundant SOX2 expression was also observed in these cells (Fig. 6A and B) , which was dramatically reduced upon BRD4-NUT knockdown (Fig. 6C and D) , suggesting that BRD4-NUT also regulates SOX2 in these cells. Furthermore, knocking down SOX2 in these NMCs also significantly induced differentiation and inhibited sphere formation ( Supplementary Fig. S8 ). In conclusion, SOX2 overexpression and the ability to form spheres are common phenomena observed in all BRD4-NUT-expressing NMCs tested, further supporting that SOX2 functions as an important target of BRD4-NUT to stimulate the stem cell-like growth property.
BRD4-NUT recruits p300 to activate in situ gene transcription To further understand the respective roles of BRD4 and BRD4-NUT in SOX2 activation, we performed mechanistic studies using the LacO transgene array for visualizing in situ transcription in live cells (35) . In this system, a transcription unit composed of 256 copies of the lac operator (LacO), 96 copies of the tetracycline response element (TRE), a minimal CMV promoter, 24 repeats of MS2 translational operators (MS2 repeats), and a polyadenylation signal was stably integrated into the U2OS genome (35) . The integrated transgene array in the resulting U2OS 2-6-3 cell line is visualized by expression of a Lac repressor binding protein (LacI)-CHERRY fusion, whereas the transcribed MS2 operator RNA is detected by accumulations of the RNA-specific binding protein, MS2 coat-YFP fusion protein (YFP-MS2), at the locus (35) . This in situ transcription assay allowed us to directly visualize transcriptional activities associated with either BRD4 or BRD4-NUT at individual transcription sites in single living cells. We showed that BRD4-NUT, and especially the NUT protein, tethered to the LacO array through LacI-CHERRY fusion strongly activated transcription of MS2 operators even in the absence of tetracycline- controlled transactivator and Dox, whereas BRD4 long and short isoforms tethered to the transgene array did not have the same effect ( Fig. 7A and B) . These results are in line with the data in Fig. 4 showing that BRD4-NUT knockdown caused efficient inhibition of SOX2 expression but BRD4 knockdown did not have the same effect.
The NUT moiety of the BRD4-NUT fusion protein has been shown to interact with p300 and to stimulate its catalytic activity (12) . Immunofluorescent staining showed that p300 was sequestered to the LacO locus by LacI-CHERRY-tagged NUT or BRD4-NUT in all of the cells expressing these proteins (Fig. 7A) . In contrast, p300 was not recruited to the LacO transgene array in cells expressing either LacI-CHERRY or the BRD4 fusion proteins. Enrichment of p300 at the LacI-CHER-RY-NUT-associated LacO locus was even significantly higher than those observed with VP16-activation domain (Fig. 7A) , which is a strong transcription activator that binds p300. These results suggest that p300 may be recruited by BRD4-NUT to support SOX2 transcription activation in NMC. Indeed, p300 colocalizes with BRD4-NUT in punctate chromatin foci and also associates with the SOX2 gene in HCC2429 (Supplementary Fig. S9 ). Treatment of HCC2429 with p300 inhibitor, C646, led to a complete dispersion of the BRD4-NUT and p300 foci (Supplementary Fig. S9A; ref. 12 ). More importantly, C646 treatment also caused up to 65% reduction of SOX2 expression within 4 hours, whereas expression of a known BRD4 target, cyclin D1 (CCND1), was not affected (Fig. 7C and D) . Together, these studies provide mechanistic evidences to support that BRD4-NUT is playing a dominating role in stimulating SOX2 expression through gain of function recruitment of p300.
Discussion
BRD4 has been identified as a critical therapeutic target in a variety of human cancers. However, the underlying mechanisms by which BRD4 contributes to cancer development are not clearly understood. In this study, we discovered stem celllike sphere growth properties in NMC cancer cells. We found that the stem cell marker SOX2 was expressed at a much higher level in NMCs than in ESCs. BRD4-NUT is recruited to the SOX2 promoter and is required for the abnormal induction of SOX2, which in turn drives the stem cell-like sphere growth and transformation in NMC. SOX2 knockdown phenocopied the effects of BRD4-NUT inhibition introduced by either JQ1 þ or siRNA, including the stimulation of cellular differentiation and abrogation of stem cell-like sphere formation, whereas SOX2 expression from an exogenous promoter resistant to BET regulation rescued the differentiation and growth suppression phenotype. We also detected overexpression of SOX2 in primary NMC tumors, providing evidence for the in vivo role of SOX2 overexpression in NMC. We therefore discovered SOX2 as a previously unknown downstream target of BRD4-NUT in NMC. Recent studies revealed that the stem cell self-renewal feature is shared with tumor cells and that the stem cell regulatory networks contribute to the ESC-like phenotype displayed by many aggressive tumors (28, 41) . In line with our findings, high SOX2 expression and oncogenic SOX2 amplification have been frequently detected during the formation of other squamous carcinomas (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . SOX2 self-renewal capacity has been linked to its ability to drive tumorigenic initiation and progression (17, 25, 27, 32, 33) . These studies support our finding that SOX2 functions as a key oncogenic driver of the highly aggressive NMC squamous cell carcinomas. In addition, SOX2 0 s ability to suppress differentiation-associated genes, as reported previously (16) , may contribute to the poorly differentiated NMC morphology.
The molecular mechanisms that regulate SOX2 expression during oncogenesis remain unclear. In this study, we show that both BRD4-NUT and BRD4 are recruited to the SOX2 gene. This is consistent with recent studies demonstrating that BRD4 is selectively enriched at super-enhancers of key oncogenic genes, and that super-enhancers are present at the master ESC regulator genes, such as SOX2 (7, 43) . Surprisingly, although BRD4 is clearly recruited to the SOX2 promoter, knockdown of BRD4 does not have the same inhibition effect on SOX2 expression as observed with BRD4-NUT knockdown (Figs. 3 and 4) , suggesting that stimulation of SOX2 superactivation in NMC is a gain of function for BRD4-NUT. This conclusion is further supported by our mechanistic studies using the LacO transgene array. We showed that BRD4-NUT, and even NUT alone, tethered to the LacO array is able to recruit p300 and to strongly stimulate the transgene activation, whereas BRD4 tethered to the same array does not have this activity. Recruitment and activation of p300 by BRD4-NUT could result in histone hyperacetylation and enrichment of additional BRD4-NUT/BRD4, as well as other transcriptional factors, to stimulate SOX2 overexpression. In line with this notion, inhibition of p300 represses SOX2 transcription in NMC (Fig. 7C and D) . Together, our mechanistic studies provide novel insights for understanding how BRD4-NUT oncogene alters BRD4 function to contribute to oncogenic progression. Similar to the inhibition of BRD4-NUT using JQ1 þ or siRNAs, SOX2 knockdown induces differentiation and inhibits sphere formation. Exogenous SOX2 efficiently rescues the differentiation and proliferation suppression in JQ1 þ or NUT siRNAtreated cells. These results suggest that SOX2 is involved in the BRD4-NUT pathways to maintain the undifferentiated cellular proliferation in NMC. However, it is possible that the cumulative action of many growth-promoting genes, including c-MYC (7, 15) , constitutes the BRD4-NUT downstream functional networks to support NMC transformation. Nonetheless, our collective results provide evidence that SOX2 is at least partly responsible for maintaining the NMC cells in the undifferentiated and highly proliferative state. It has been well established that cancer stem cells are more resistant to conventional cancer therapies (47) . Elimination of cancer stem cells has therefore become an important approach for preventing tumor progression, recurrence, and metastasis. Nearly all of NMCs are refractory to conventional chemotherapeutic regimens (2) . Because SOX2 has been shown to confer chemotherapy resistance to cancer stem cells (19, (48) (49) (50) , it is possible that the SOX2-associated sphere growth features contribute to the chemoresistant nature of NMCs. It will be promising to further investigate this potential SOX2 function in NMC tumorigenesis and to determine if this could be an efficient therapeutic target for overcoming the NMC chemoresistance.
BRD4 has become an important target for cancer therapy. In this study, we present the first line of evidence to show that alteration of BRD4 function by BRD4-NUT oncogenic mutation causes abnormal SOX2 overexpression, which contributes to the oncogenic mechanism of the aggressive t(15;19) cancers. Because abnormal stem cell self-renewal is frequently observed during tumor formation and metastasis, the aberrant stem cell-like proliferation associated with BRD4 dysregulation observed in the highly malignant NMCs may have implications for studying other BRD4-associated tumors. It will be interesting to test if BRD4 function is also altered in other BRD4-associated cancers through different mechanism(s) to cause stimulation of SOX2 expression and/or cancer stem cell-like features. These studies may reveal the mechanisms underlying the oncogenic activity of BRD4 in these tumors and promote more effective anticancer strategies to overcome cancer stem cell resistance to chemotherapy.
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